Analytical Data
-
Gene name
QDPR
- Application
-
Alternative Names
DHPR; PKU2; SDR33C1; HDHPR; 6,7-Dihydropteridine Reductase; Short Chain Dehydrogenase/Reductase Family 33C,Member 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P09417
-
Expression Region
Met1~Phe244
-
Molecular Weight
30kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of QDPR (quinoid dihydropteridine reductase) and its recombinant proteins is significant due to its role in the metabolism of tetrahydrobiopterin (BH4), a critical cofactor involved in the biosynthesis of neurotransmitters such as dopamine, serotonin, and norepinephrine. Deficiencies in QDPR can lead to neurotransmitter deficiencies, resulting in conditions like phenylketonuria (PKU) and other neurological disorders. Research into the recombinant form of QDPR has been motivated by the need for therapeutic interventions for patients with these genetic disorders. The production of recombinant QDPR proteins offers a means to understand the enzyme's structure-function relationships, improve diagnostic tools, and explore potential gene therapy approaches. Advanced techniques in molecular cloning and protein expression systems have facilitated the generation of these proteins, allowing scientists to study their biochemical properties, catalytic mechanisms, and interactions with other biomolecules. Furthermore, recombinant QDPR proteins hold promise for developing enzyme replacement therapies that could alleviate the symptoms of associated disorders, ultimately contributing to improved patient outcomes. As such, understanding the dynamics of QDPR and its recombinant proteins is a key area of research in biochemistry and molecular medicine, bridging the gap between fundamental science and practical applications in therapeutic development.
